Dean Capital Investments Management LLC cut its holdings in Agilent Technologies Inc (NYSE:A) by 2.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 5,833 shares of the medical research company’s stock after selling 166 shares during the quarter. Dean Capital Investments Management LLC’s holdings in Agilent Technologies were worth $393,000 as of its most recent SEC filing.
Other large investors have also added to or reduced their stakes in the company. Xact Kapitalforvaltning AB increased its holdings in Agilent Technologies by 15.0% during the 3rd quarter. Xact Kapitalforvaltning AB now owns 47,513 shares of the medical research company’s stock worth $3,352,000 after purchasing an additional 6,200 shares in the last quarter. Creative Planning increased its holdings in Agilent Technologies by 6.6% during the 3rd quarter. Creative Planning now owns 17,482 shares of the medical research company’s stock worth $1,233,000 after purchasing an additional 1,083 shares in the last quarter. Robeco Institutional Asset Management B.V. grew its holdings in shares of Agilent Technologies by 6.4% in the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 172,434 shares of the medical research company’s stock valued at $12,164,000 after acquiring an additional 10,419 shares in the last quarter. Alps Advisors Inc. bought a new position in shares of Agilent Technologies in the 3rd quarter valued at about $953,000. Finally, Cullen Frost Bankers Inc. bought a new position in shares of Agilent Technologies in the 3rd quarter valued at about $7,962,000.
Several brokerages have recently weighed in on A. Zacks Investment Research cut Agilent Technologies from a “buy” rating to a “hold” rating in a report on Wednesday, January 23rd. Deutsche Bank restated a “buy” rating and issued a $90.00 price objective on shares of Agilent Technologies in a report on Thursday, February 21st. Janney Montgomery Scott restated a “buy” rating and issued a $90.00 price objective (up previously from $80.00) on shares of Agilent Technologies in a report on Thursday, February 21st. JPMorgan Chase & Co. raised their price objective on Agilent Technologies to $85.00 and gave the company an “overweight” rating in a report on Thursday, February 21st. Finally, Bank of America restated a “buy” rating and issued a $87.00 price objective (up previously from $78.00) on shares of Agilent Technologies in a report on Thursday, February 21st. Two investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Agilent Technologies presently has a consensus rating of “Buy” and a consensus target price of $86.40.
In other Agilent Technologies news, CEO Michael R. Mcmullen sold 17,491 shares of the business’s stock in a transaction on Wednesday, January 30th. The shares were sold at an average price of $75.00, for a total transaction of $1,311,825.00. Following the sale, the chief executive officer now owns 456,430 shares of the company’s stock, valued at $34,232,250. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Rodney Gonsalves sold 6,155 shares of the business’s stock in a transaction on Wednesday, March 6th. The stock was sold at an average price of $79.79, for a total transaction of $491,107.45. The disclosure for this sale can be found here. Insiders sold 74,171 shares of company stock worth $5,764,185 over the last three months.
Shares of A opened at $80.13 on Thursday. Agilent Technologies Inc has a 12 month low of $60.42 and a 12 month high of $81.76. The company has a market cap of $25.38 billion, a PE ratio of 28.72, a price-to-earnings-growth ratio of 2.22 and a beta of 1.38. The company has a current ratio of 3.39, a quick ratio of 2.79 and a debt-to-equity ratio of 0.36.
Agilent Technologies (NYSE:A) last announced its earnings results on Wednesday, February 20th. The medical research company reported $0.76 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.73 by $0.03. Agilent Technologies had a net margin of 22.86% and a return on equity of 19.90%. The company had revenue of $1.28 billion for the quarter, compared to analysts’ expectations of $1.27 billion. During the same period last year, the firm earned $0.66 earnings per share. The business’s revenue for the quarter was up 6.0% on a year-over-year basis. As a group, equities analysts predict that Agilent Technologies Inc will post 3.06 EPS for the current year.
Agilent Technologies announced that its board has authorized a share repurchase program on Monday, November 19th that authorizes the company to buyback $1.75 billion in outstanding shares. This buyback authorization authorizes the medical research company to buy up to 8.8% of its shares through open market purchases. Shares buyback programs are typically an indication that the company’s board believes its stock is undervalued.
COPYRIGHT VIOLATION WARNING: “Agilent Technologies Inc (A) Holdings Cut by Dean Capital Investments Management LLC” was published by Fairfield Current and is the property of of Fairfield Current. If you are reading this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.fairfieldcurrent.com/news/2019/03/14/dean-capital-investments-management-llc-has-393000-stake-in-agilent-technologies-inc-a.html.
Agilent Technologies Profile
Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates through three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; laboratory software and information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies.
Featured Story: What is the price-sales ratio?
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.